Rol' Kselody v ad\"yuvantnom lechenii raka tolstoy kishki: klinicheskiy opyt primeneniya
- Authors: Trishkina E.A1
-
Affiliations:
- Issue: No 2S (2008)
- Pages: 44-49
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/275749
- ID: 275749
Cite item
Full Text
Abstract
На основании результатов крупномасштабного рандомизированного исследования X-ACT и собственного клинического опыта применения капецитабина (Кселоды) у 46 больных колоректальным раком авторы показали, что пероральный прием Кселоды в адъювантном лечении рака толстой кишки является эффективным и безопасным видом терапии во всех возрастных. группах. Препарат удобен и прост в применении, позволяет сохранять качество жизни и профессиональную активность трудоспособных больных.
Full Text
References
- Барсуков Ю.А. Адъювантная терапия - важнейший компонент в программе комплексного лечения колоректального рака //Медицинский Вестник. 2007. № 16(401). С. 9-10.
- Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108.
- Landis SH, Murray T, Bolden S, et al. Global cancer statistics, 1999. CA Cancer J Clin 1999;49(1): 8-31.
- Чисов В.И., Старинский В.В., Петрова Г.В. Злокачественные новобразования в России в 2006 (заболеваемость и смертность). М., 2008.
- O'Connell et al. J Natl Cancer Inst 2004.
- Vogel I, Soeth E, Ruder C, et al. Disseminated tumor cells in the blood and/or bone marrow of patients with colorectal carcinoma are an independent prognostic factor. Ann Oncol 2000;11(Suppl. 4):43, abstr. 183.
- International Multicentre pooled analysis of colon cancer trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-944.
- O'Connell MJ, Maillard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for six months as post-operative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15(1):246-50.
- Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122(5):321-26.
- Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, cape-citabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34(8): 1274-81.
- Twelves C, et al. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. NEJM 2005;352:2696-704.
- Twelves C, et al. 5-year overall survival update from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant treatment for stage III colon cancer. ECCO 2007: 1LB Oral.
- Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-FU/LV in stage III colon cancer: Updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. ASCO 2008 (Gastrointestinal Cancers Symposium): 274.
- Kim JS, Cho MJ, et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002;54: 403-08.
- Souglakos J, Androulakis N, Mavroudis D, et al. Multicenter dose - finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys 2003;56:1284-87.
- Vaishampayan UN, Ben-Josef E, Philip PA, et al. A singel-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 2002;53:675-79.
- F. Hoffmann-La Roche Ltd., data on file.
- Schmoll HJ, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. J Clin Oncol 2007;25:102-09.
Supplementary files
